Cancer Treatment Today

This drug is approved for specific diagnoses in which an ALK mutation can be present. There are several phase II studies suggesting activity Xalkori (crizotinib) for clear cell sarcoma. Shoffski 2019 did a prospective study that showed that the PFS with crizotinib in MET+CCSA is similar to results achieved first-line in non-selected metastatic soft tissue sarcomas with single-agent doxorubicin. r The PFS is similar to results achieved with pazopanib in previously treated sarcoma patients. There is evidence of its effectiveness also fo inflammatory myofibroblastic tumors (IMFT).
For Ewing, there is literature as well, please see the Reference section.

Schöffski P et al, Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’.Ann Oncol. 2019 Feb 1;30(2):344.

Schöffski P, Wozniak A, Stacchiotti S, et al. Activity and safety of crizotinib in patients with advanced clear cell sarcoma (CCSA) with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 CREATE. Presented at: CTOS 2018 Annual Meeting; Rome, Italy: November 14-17. Paper 018.

Fleuren ED, Roeffen MH, Leenders WP, Flucke UE, Vlenterie M, Schreuder HW, Boerman OC, van der Graaf WT, Versleijen-Jonkers YM. Expression and clinical relevance of MET and ALK in Ewing sarcomas. Int J Cancer. 2013 Jul 15;133(2):427-36.

M. Wood et al, Successful Crizotinib-targeted Therapy of Pediatric Unresectable ERC1::ALK Fusion Sarcoma. J. Ped Sarcoma https://journals.lww.com/jpho-online/fulltext/2024/03000/successful_crizotinib_targeted_therapy_of.25.aspx

Schöffski P, Sufliarsky J, Gelderblom H, et al. Prospective trial of crizotinib (C) in patients (PTS) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alternations: EORTC phase 2 study 90101 “CREATE.” Presented at: CTOS 2018 Annual Meeting; Rome, Italy: November 14-17. Paper 01
.